Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ulotaront
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : $30.0 million
Deal Type : Licensing Agreement
Otsuka and Sumitomo Revise License Agreement
Details : Under the license agreement, Otsuka holds exclusive rights to develop, manufacture, and commercialize SEP-363856 (ulotaront), TAAR1 agonist. It is being evaluated with the patient for Schizophrenia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 15, 2024
Lead Product(s) : Ulotaront
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : $30.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Recipient : Salipro Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Through collaboration, Salipro will utilize its expertise in stabilizing challenging membrane proteins via its Salipro® technology to advance Sumitomo's drug discovery program by characterizing a drug with the desired therapeutic properties against a se...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 09, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Recipient : Salipro Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Gemtesa (vibegron) is a once-daily beta-3 adrenergic receptor (β3) agonist, is currently under investigation for the treatment of men with overactive bladder (OAB) symptoms receiving pharmacological therapy for benign prostatic hyperplasia.
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2023
Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Sumitomo Pharma and Pfizer in Canada Receive Health Canada Approval for MYFEMBREE®
Details : Myfembree (relugolix, estradiol, and norethindrone acetate) has received a dual indication approval, making it the first Health Canada-approved oral treatment to manage uterine fibroids and endometriosis.
Product Name : Myfembree
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2023
Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Recipient : Gedeon Richter
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ryeqo (relugolix, estradiol, and norethisterone acetate) receives positive opinion by CHMP recommending approval in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
Product Name : Ryeqo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2023
Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Recipient : Gedeon Richter
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ulotaront
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SEP-363856 (ulotaront) is a TAAR1 agonist with 5-HT1A agonist activity, is currently under investigation for the treatment of schizophrenia, generalized anxiety disorder and the adjunctive treatment of MDD with additional indications under consideration.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 31, 2023
Lead Product(s) : Ulotaront
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Study Phase : Approved FDF
Recipient : Kyorin Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : KYORIN will grant Sumitomo Pharma the exclusive rights to develop, manufacture, and commercialize the therapeutic agent for OAB called Vibegron in in Taiwan and Other Asian Countries, and Sumitomo Pharma will develop, manufacture, and commercialize the C...
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 03, 2023
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Recipient : Kyorin Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : TP-3654
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TP-3654 is an oral investigational inhibitor of PIM kinases, which has potential antitumor and anti-fibrotic effects through multiple pathways, including induction of apoptosis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2022
Lead Product(s) : TP-3654
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TP-1287 is enzymatically cleaved, yielding active moiety, potent inhibitor of CDK9. Inhibiting CDK9 is thought to downregulate transcription of target genes, including MCL-1, reducing leukemic blast viability in MCL-1–dependent hematologic malignancies...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2022
Details : DSP-0390 is an investigational emopamil-binding protein (EBP) inhibitor. EBP is an endoplasmic reticulum membrane protein involved in cholesterol biosynthesis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 18, 2022